Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma

Bookmark and Share
Published: 26 Jun 2020
Views: 424
Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy

Prof Carmelo Carlo-Stella speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He gives an overview of this phase II trial, which assessed the efficacy of loncastuximab tesirine for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma.

Prof Carlo-Stella presents the promising initial findings from this study, which could offer a new treatment option for heavily-pretreated patients, who have failed prior therapies.